Your browser doesn't support javascript.
loading
Uncovering the dynamic effects of DEX treatment on lung cancer by integrating bioinformatic inference and multiscale modeling of scRNA-seq and proteomics data.
Chen, Minghan; Xu, Chunrui; Xu, Ziang; He, Wei; Zhang, Haorui; Su, Jing; Song, Qianqian.
Affiliation
  • Chen M; Department of Computer Science, Wake Forest University, Winston-Salem, NC, USA.
  • Xu C; Genetics, Bioinformatics, and Computational Biology, Virginia Tech, Blacksburg, VA, USA.
  • Xu Z; Department of Computer Science, Wake Forest University, Winston-Salem, NC, USA; Department of Chemistry, Wake Forest University, Winston-Salem, NC, USA.
  • He W; Genetics, Bioinformatics, and Computational Biology, Virginia Tech, Blacksburg, VA, USA.
  • Zhang H; Department of Mathematics and Statistics, Wake Forest University, Winston-Salem, NC, USA.
  • Su J; Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Song Q; Center for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, NC, USA; Department of Cancer Biology, Wake Forest School of Medicine, Winston Salem, NC, USA. Electronic address: qsong@wakehealth.edu.
Comput Biol Med ; 149: 105999, 2022 10.
Article de En | MEDLINE | ID: mdl-35998480
ABSTRACT
Lung cancer is one of the leading causes of cancer-related death, with a five-year survival rate of 18%. It is a priority for us to understand the underlying mechanisms affecting lung cancer therapeutics' implementation and effectiveness. In this study, we combine the power of Bioinformatics and Systems Biology to comprehensively uncover functional and signaling pathways of drug treatment using bioinformatics inference and multiscale modeling of both scRNA-seq data and proteomics data. Based on a time series of lung adenocarcinoma derived A549 cells after DEX treatment, we first identified the differentially expressed genes (DEGs) in those lung cancer cells. Through the interrogation of regulatory network of those DEGs, we identified key hub genes including TGFß, MYC, and SMAD3 varied underlie DEX treatment. Further gene set enrichment analysis revealed the TGFß signaling pathway as the top enriched term. Those genes involved in the TGFß pathway and their crosstalk with the ERBB pathway presented a strong survival prognosis in clinical lung cancer samples. With the basis of biological validation and literature-based curation, a multiscale model of tumor regulation centered on both TGFß-induced and ERBB-amplified signaling pathways was developed to characterize the dynamic effects of DEX therapy on lung cancer cells. Our simulation results were well matched to available data of SMAD2, FOXO3, TGFß1, and TGFßR1 over the time course. Moreover, we provided predictions of different doses to illustrate the trend and therapeutic potential of DEX treatment. The innovative and cross-disciplinary approach can be further applied to other computational studies in tumorigenesis and oncotherapy. We released the approach as a user-friendly tool named BIMM (Bioinformatic Inference and Multiscale Modeling), with all the key features available at https//github.com/chenm19/BIMM.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Biologie informatique / Tumeurs du poumon Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Comput Biol Med Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Biologie informatique / Tumeurs du poumon Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Comput Biol Med Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique